1. Binding assay of human Dectin-1 variants to DNA/β-glucan complex for active-targeting delivery of antisense DNA
- Author
-
Ryoma Kira, Yasuo Morimoto, Shinichi Mochizuki, Nobuaki Fujiwara, Hiroto Izumi, and Kazuo Sakurai
- Subjects
Gene isoform ,beta-Glucans ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,chemistry.chemical_compound ,Drug Delivery Systems ,Complementary DNA ,Carbohydrate Conformation ,Tumor Cells, Cultured ,Humans ,Lectins, C-Type ,Gene ,Binding Sites ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,DNA ,General Medicine ,Transfection ,Oligonucleotides, Antisense ,Molecular biology ,Exon skipping ,0104 chemical sciences ,Cell culture ,Drug delivery - Abstract
The lectin Dectin-1 is a good target for β-glucan-mediated drug delivery. Although many murine studies of Dectin-1 have been performed, its human analog has not been studied well in terms of being a drug delivery target. We thus analyzed human Dectin-1 cDNA obtained from chronic myelogenous leukemia-derived cells, CML-1, and confirmed the findings of previous studies that there are many isoforms of human Dectin-1 due to exon skipping, although murine Dectin-1 has only two forms. When we transfected the Dectin-1 gene into a non-Dectin-1-expressing cell line and examined cellular uptake of the antisense DNA/β-glucan complex, we confirmed that expression of the target gene was effectively suppressed through β-glucan/Dectin-1-mediated uptake. The present results suggest that the β-glucan complex would be an effective tool to deliver antisense oligonucleotide (AS-ODN) to Dectin-1-expressing cells not only for mice but also for humans.
- Published
- 2021